Kihyuk Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kihyuk Shin has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Moon-Bum Kim
Department of Dermatology, School of Medicine Pusan National University Busan Korea
37 shared publications - Byung-Soo Kim
Department of Dermatology, School of Medicine Pusan National University Busan Korea
36 shared publications - Hyun-Chang Ko
Department of Dermatology, School of Medicine Pusan National University Busan Korea
34 shared publications - Hoon-Soo Kim
Department of Dermatology, School of Medicine Pusan National University Busan Korea
33 shared publications - Jungsoo Lee
Department of Dermatology, School of Medicine Pusan National University Busan Korea
14 shared publications - Kyung-Nam Bae
Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
10 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 23 (1) , 71-76
Long-term treatment of psoriasis with ixekizumab in a patient with alcoholic liver cirrhosis: a 4-year case report
- 30 June 2026
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 23 (1) , 71-76
Open AccessLong-term treatment of psoriasis with ixekizumab in a patient with alcoholic liver cirrhosis: a 4-year case report
- Open Access
- 30 June 2026
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 23 (1) , 77-81
Reactivation of alopecia areata progressing to universalis during secukinumab treatment for psoriasis: a case report
- 30 June 2026
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 23 (1) , 77-81
Open AccessReactivation of alopecia areata progressing to universalis during secukinumab treatment for psoriasis: a case report
- Open Access
- 31 March 2026
- Published by Korean Society for Medical Mycology in Journal of Mycology and Infection
- Vol. 1 (31)
Primary Cutaneous Cryptococcosis Mimicking Basal Cell Carcinoma
Journal of mycology and infection (Acronym: JMI, Abbreviation: J Mycol Infect) aims to publish articles of exceptional interests in the field of medical mycology. The journal originally was launched in 1996 as the Korean Journal of Medical Mycology and has reformed into the current state beginning on March of 2018. The contents of the journal should elucidate important microbiological fundamentals and provide qualitative insights to respective clinical aspects. JMI underlines the submission of novel findings and studies in clinical mycology that are enriched by analyses achieved through investigative methods.
- 31 March 2026
- Published by Korean Society for Medical Mycology in Journal of Mycology and Infection
- Vol. 1 (31)
Open AccessPrimary Cutaneous Cryptococcosis Mimicking Basal Cell Carcinoma
Journal of mycology and infection (Acronym: JMI, Abbreviation: J Mycol Infect) aims to publish articles of exceptional interests in the field of medical mycology. The journal originally was launched in 1996 as the Korean Journal of Medical Mycology and has reformed into the current state beginning on March of 2018. The contents of the journal should elucidate important microbiological fundamentals and provide qualitative insights to respective clinical aspects. JMI underlines the submission of novel findings and studies in clinical mycology that are enriched by analyses achieved through investigative methods.
- Open Access
- 16 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (10) , 2091-2101
Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
Background: Alopecia areata (AA) affects all ages, genders, and ethnicities. AA severely impacts patients' quality of life. Treatments indicated for AA have only been approved since 2022/2023. While some Asia Pacific (APAC) countries/regions have national or regional guidelines, many lack AA‐specific guidance or have not updated existing guidelines to incorporate recently approved treatments. Methods: To better inform treatment decisions, 18 dermatologists from Australia, China, India, Korea, Malaysia, Singapore, Taiwan, and Thailand completed a three‐round Delphi‐based consensus process involving survey completion, open discussion, and statement voting. A consensus for Likert‐type and multiple‐choice statements was defined as ≥ 70% agreement or disagreement. Results: Consensus was achieved on 140 statements. The panel recognizes that AA is clinically heterogeneous and imposes a considerable burden on patients and their families. Trichoscopy is deemed essential for diagnosing and monitoring AA, while skin biopsy is reserved for when the cause of hair loss is unclear. In terms of disease severity, moderate AA is defined as 21%–49% hair loss and severe AA as ≥ 50% hair loss. Regarding treatment, topical corticosteroids are recommended in children < 12 years. For patients aged ≥ 12 years, topical and intralesional corticosteroids could be used for mild‐to‐moderate AA, while Janus kinase inhibitors and systemic corticosteroids have a role in moderate‐to‐severe AA. Adjuvant minoxidil could also be used in chronic AA. Conclusions: This modified Delphi‐based consensus provides a practical, region‐focused framework to standardize the diagnosis and management of AA across diverse APAC healthcare settings in hope of improving patient outcomes.
- 16 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (10) , 2091-2101
Open AccessEpidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
Background: Alopecia areata (AA) affects all ages, genders, and ethnicities. AA severely impacts patients' quality of life. Treatments indicated for AA have only been approved since 2022/2023. While some Asia Pacific (APAC) countries/regions have national or regional guidelines, many lack AA‐specific guidance or have not updated existing guidelines to incorporate recently approved treatments. Methods: To better inform treatment decisions, 18 dermatologists from Australia, China, India, Korea, Malaysia, Singapore, Taiwan, and Thailand completed a three‐round Delphi‐based consensus process involving survey completion, open discussion, and statement voting. A consensus for Likert‐type and multiple‐choice statements was defined as ≥ 70% agreement or disagreement. Results: Consensus was achieved on 140 statements. The panel recognizes that AA is clinically heterogeneous and imposes a considerable burden on patients and their families. Trichoscopy is deemed essential for diagnosing and monitoring AA, while skin biopsy is reserved for when the cause of hair loss is unclear. In terms of disease severity, moderate AA is defined as 21%–49% hair loss and severe AA as ≥ 50% hair loss. Regarding treatment, topical corticosteroids are recommended in children < 12 years. For patients aged ≥ 12 years, topical and intralesional corticosteroids could be used for mild‐to‐moderate AA, while Janus kinase inhibitors and systemic corticosteroids have a role in moderate‐to‐severe AA. Adjuvant minoxidil could also be used in chronic AA. Conclusions: This modified Delphi‐based consensus provides a practical, region‐focused framework to standardize the diagnosis and management of AA across diverse APAC healthcare settings in hope of improving patient outcomes.
- Open Access
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38
A Case of Severe Diffuse Non-Scarring Alopecia in Systemic Lupus Erythematosus Treated by Topical Corticosteroid/Vitamin D Analogue Ointment
Kim HS, et al. Ann Dermatol. 2026 ;38:e65. https://doi.org/10.5021/ad.26.058
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38
Open AccessA Case of Severe Diffuse Non-Scarring Alopecia in Systemic Lupus Erythematosus Treated by Topical Corticosteroid/Vitamin D Analogue Ointment
Kim HS, et al. Ann Dermatol. 2026 ;38:e65. https://doi.org/10.5021/ad.26.058
- Open Access
- 31 December 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (2) , 81-88
Coexistence of psoriasis and vitiligo: a case series of four patients and review of the literature
Taeyeong Kim, Jungsoo Lee, Kihyuk Shin, Hoon-Soo Kim, Hyun-Chang Ko, Moon-Bum Kim, Byungsoo Kim. Journal of the Korean Society for Psoriasis 2025;22:81-8. https://doi.org/10.23203/JKSP.2025.22.2.81
- 31 December 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (2) , 81-88
Open AccessCoexistence of psoriasis and vitiligo: a case series of four patients and review of the literature
Taeyeong Kim, Jungsoo Lee, Kihyuk Shin, Hoon-Soo Kim, Hyun-Chang Ko, Moon-Bum Kim, Byungsoo Kim. Journal of the Korean Society for Psoriasis 2025;22:81-8. https://doi.org/10.23203/JKSP.2025.22.2.81
- 10 May 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (5) , 641-653
Dosis‐Wirkungs‐Beziehung zwischen Alkoholkonsum und Psoriasis: Systematische Übersicht und Metaanalyse
Zusammenfassung: Verschiedene Studien zur Assoziation zwischen Psoriasis und Alkoholkonsum ergeben kein einheitliches Bild. Nach unserer Kenntnis wurde allerdings bisher noch keine Metaanalyse zur Dosis‐Wirkungs‐Beziehung durchgeführt. Diese Studie untersucht die Assoziation zwischen Alkoholkonsum und Psoriasis. Die Datenbanksuche wurde am 27. Juli 2021 in den Datenbanken Embase und MEDLINE durchgeführt. Zur Analyse der Dosis‐Wirkungs‐Beziehung wurde die Restricted‐cubic‐Spline‐Analyse eingesetzt. Insgesamt konnten wir 3904 Studien identifizieren, von denen letztlich 48 mit einer Gesamtpopulation von 1 702 847 Personen in die Metaanalyse einbezogen wurden. Alkoholkonsum war positiv assoziiert mit Psoriasis (Odds Ratio [OR] 1,47; 95%‐Konfidenzintervall [KI] 1,27–1,70). Außerdem fand sich eine positive OR für Psoriasis bei Männern (OR 1,84; 95% KI 1,13–3,01), nicht aber bei Frauen (OR 1,22; 95% KI 0,97–1,54). Auf der Basis von acht Studien (drei Kohortenstudien und fünf Fall‐Kontroll‐Studien) ergab die Analyse, dass sich für jedes zusätzliche Gramm an täglichem Alkoholkonsum die OR für Psoriasis um 4% erhöht. Wir konnten eine positive Assoziation zwischen Alkoholkonsum und Psoriasis feststellen. Diese Assoziation ist deutlicher in der Gruppe von Personen, die täglich mehr als 45 Gramm Alkohol zu sich nehmen (dies entspricht täglich 3,2 Gläsern eines alkoholischen Getränks).
- 10 May 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (5) , 641-653
Dosis‐Wirkungs‐Beziehung zwischen Alkoholkonsum und Psoriasis: Systematische Übersicht und Metaanalyse
Zusammenfassung: Verschiedene Studien zur Assoziation zwischen Psoriasis und Alkoholkonsum ergeben kein einheitliches Bild. Nach unserer Kenntnis wurde allerdings bisher noch keine Metaanalyse zur Dosis‐Wirkungs‐Beziehung durchgeführt. Diese Studie untersucht die Assoziation zwischen Alkoholkonsum und Psoriasis. Die Datenbanksuche wurde am 27. Juli 2021 in den Datenbanken Embase und MEDLINE durchgeführt. Zur Analyse der Dosis‐Wirkungs‐Beziehung wurde die Restricted‐cubic‐Spline‐Analyse eingesetzt. Insgesamt konnten wir 3904 Studien identifizieren, von denen letztlich 48 mit einer Gesamtpopulation von 1 702 847 Personen in die Metaanalyse einbezogen wurden. Alkoholkonsum war positiv assoziiert mit Psoriasis (Odds Ratio [OR] 1,47; 95%‐Konfidenzintervall [KI] 1,27–1,70). Außerdem fand sich eine positive OR für Psoriasis bei Männern (OR 1,84; 95% KI 1,13–3,01), nicht aber bei Frauen (OR 1,22; 95% KI 0,97–1,54). Auf der Basis von acht Studien (drei Kohortenstudien und fünf Fall‐Kontroll‐Studien) ergab die Analyse, dass sich für jedes zusätzliche Gramm an täglichem Alkoholkonsum die OR für Psoriasis um 4% erhöht. Wir konnten eine positive Assoziation zwischen Alkoholkonsum und Psoriasis feststellen. Diese Assoziation ist deutlicher in der Gruppe von Personen, die täglich mehr als 45 Gramm Alkohol zu sich nehmen (dies entspricht täglich 3,2 Gläsern eines alkoholischen Getränks).